LDL particle number (LDL-P) and HDL particle number (HDL-P) measured by NMR have been shown to have significant and independent associations with cardiovascular disease events regardless of LDL cholesterol (LDL-C) levels.
Click here to view a partial bibliography.
Clinical Utility of Inflammatory Markers and Advanced Lipoprotein Testing: Advice from an Expert Panel of Lipid Specialists Journal of Clinical Lipidology, 2011;5(5);338-367
Clinical Implications of Discordance between Low-Density Lipoprotein Cholesterol and Particle Number: Multi-Ethnic Study of Atherosclerosis Journal of Clinical Lipidology, 2011;5(2);105-113
Underappreciated Opportunities for Low Density Lipoprotein Management in Patients with Cardiometabolic Risk Atherosclerosis. 2010;213:1-7
Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices Clinical Chemistry. 2009;55:407-419
Low Density Lipoprotein and Apolipoprotein B: Clinical Use in Patients with Coronary Heart Disease Current Cardiology Reports. 2009;11:468-475
Lipoprotein Management in Patients with Cardiometabolic Risk: Consensus Statement from the American Diabetes Association and the American College of Cardiology Foundation Diabetes Care 2008;31(4);811-812
LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study – Implications for LDL Management J Clin Lipidology. 2007;1:583-592
Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclass Predict Coronary Events and are Favorably Changed by Gemfibrozil Thearpy in the veterans Affairs High-Density Lipoprotein Intervention Trial Circulation. 2006;113:1556-1563
Click here to view a partial bibliography.
Click on the links below to view select abstracts
High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary Events: Multi-Ethnic Study of Atherosclerosis (MESA) J Am Coll Cardiol 2012;60:508-16Clinical Utility of Inflammatory Markers and Advanced Lipoprotein Testing: Advice from an Expert Panel of Lipid Specialists Journal of Clinical Lipidology, 2011;5(5);338-367
Clinical Implications of Discordance between Low-Density Lipoprotein Cholesterol and Particle Number: Multi-Ethnic Study of Atherosclerosis Journal of Clinical Lipidology, 2011;5(2);105-113
Underappreciated Opportunities for Low Density Lipoprotein Management in Patients with Cardiometabolic Risk Atherosclerosis. 2010;213:1-7
Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices Clinical Chemistry. 2009;55:407-419
Low Density Lipoprotein and Apolipoprotein B: Clinical Use in Patients with Coronary Heart Disease Current Cardiology Reports. 2009;11:468-475
Lipoprotein Management in Patients with Cardiometabolic Risk: Consensus Statement from the American Diabetes Association and the American College of Cardiology Foundation Diabetes Care 2008;31(4);811-812
LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study – Implications for LDL Management J Clin Lipidology. 2007;1:583-592
Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclass Predict Coronary Events and are Favorably Changed by Gemfibrozil Thearpy in the veterans Affairs High-Density Lipoprotein Intervention Trial Circulation. 2006;113:1556-1563
